Abstract
Background: Severe Combined Immunodeficiency (SCID) is a rare genetic disease that affects newborn immune system and costs healthcare system a substantial amount of money. Screening and stem cell transplant may offer a cost-effective alternative to the current medical practice. Objective: To determine the cost-effectiveness of screening newborn for SCID with subsequent stem cell transplant versus standard of care. Materials and Methods: An economic evaluation was proposed, using Treeage software on a set of evidence-based propabilities and variables. Outcomes: as shown on the tree, we count the death from SCID. Its given the payoff 1, while the survival is payoff 0. The outcome of interest is death averted by screening live birth and implementing subsequent stem cell transplant for those who tested +ve.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
